Disease relevance of ruthenium

• The technique of the ruthenium-106 irradiation of conjunctival melanoma is described and the first clinical results are reported [1].
• Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma [2].
• CONCLUSION: Solitary peripheral retinal hemangioma can be ablated effectively by ruthenium-106 brachytherapy [2].
• Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques [3].
• A non-comparative case observation study estimated the feasibility of brachytherapy for retinoblastoma with a newly designed ruthenium-106 plaque (label: CXS) with an 8-mm diameter of the irradiation zone [4].

High impact information on ruthenium

• Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal haemangioma in Sturge-Weber syndrome [5].
• After excision of the tumor including lamellar sclerectomy and keratectomy, a ruthenium-106 plaque was sutured to the sclera, and a total dose of 290 and 320 Gy, respectively, was delivered to the tumor bed [6].
• Partition of ruthenium-106 between the fresh water environment and crayfish [7].

Chemical compound and disease context of ruthenium

• METHODS: In a retrospective study, records were evaluated of 72 patients who underwent cataract surgery after treatment of choroidal melanoma (35 were treated with iodine-125 plaques, 27 with ruthenium-106 plaques, eight by tumor excision, and two with proton beam irradiation) [8].

Biological context of ruthenium

• PURPOSE: To analyze survival, radiation-related complications, local recurrence, enucleation, and visual acuity after ruthenium-106 irradiation of malignant uveal melanoma [9].

Anatomical context of ruthenium

• On the assumption that the diagnosis was consistent with an amelanotic ciliary body melanoma, a transscleral resection with adjuvant ruthenium-106 brachytherapy was performed [10].

Analytical, diagnostic and therapeutic context of ruthenium

• INTERVENTION: Brachytherapy using 106-ruthenium/106-rhodium plaques was performed [2].
• PURPOSE: The influence of the dose-rate on tumor response in radiotherapy with 106-Ruthenium eye plaques has been investigated in an experimental tumor system [11].
• PATIENTS AND METHODS: The authors studied the positions of ruthenium-106 (Ru-106) plaques in 43 patients treated for choroidal tumors by B-scan echography on the first postoperative day [12].
• Echographic evaluation of choroidal melanomas treated with ruthenium-106 plaques: the treatment failures [13].
• We studied the effect of transpupillary thermotherapy (TTT) by a diode laser at 810 nm combined with episcleral ruthenium-106 plaque treatment (106Ru) on lens transparency in patients with choroidal melanoma [14].

References